About

About BIONOVIS SA - COMPANHIA BRASILEIRA DE BIOTECNOLOGIA FARMACEUTICA Bionovis is a Brazilian pharmaceutical biotechnology company whose objective is to promote the research & development, manufacturing, distribution, and commercialization of highly complex biopharmaceuticals. We constantly invest in highly qualified human resources and in the acquisition of equipment and technology. This structure allows us to fully produce several innovative biological, biosimilar and biopharmaceutical medicines for the treatment of various pathologies, increasing access to high-technology medicines for patients. In more than a decade of operation, we have built partnerships with major global leaders in the biopharmaceutical sector. Through these partnerships, we receive the complete technology to produce innovative biopharmaceuticals and biosimilars. In our history, we have already positively impacted around 1 million patients, through the provision of more than 16 million vials and syringes of biopharmaceuticals. We are committed to ensuring Brazil's self-sufficiency in the development and manufacturing of high-quality, highly complex biological products, increasingly expanding the access of Brazilians to these medicines. Aligned with global standards and requirements required of the National Health Surveillance Agency – ANVISA (approved in November 2023 – API and December 2024 – Fill and Finish), regulatory agencies in the United States (Food and Drug Administration – FDA – expected for 2027) and Europe (European Medicines Agency – EMA – expected for 2027). Bionovis is looking for opportunities to license biological and biosimilar products for the Brazilian market and offers C(D)MO capabilities for Brazil and Latin America.